Research-based pharmaceutical industry launches collaborative framework to tackle NCDs
The research-based pharmaceutical industry launches today a Framework for Action to respond to concerns that cardiovascular disease, cancer, diabetes and chronic respiratory diseases are posing mounting threats to public health as well as public and private finances worldwide. The industry’s ten-point Framework scopes out specific areas of action to tackle non-communicable diseases (NCDs) including innovation,...
Read moreWHA 66 agenda item 17.1 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products
IFPMA Statement under WHA 66 agenda item 17.1 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on this...
Read moreThe African Global Health Leaders Fellowship launched to support the future of health in Africa
The African Global Health Leaders Fellowship launched to support the future of health in Africa Geneva, 24 January 2018│ The Centre on Global Health Security at Chatham House, the Global Health Centre at the Graduate Institute and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced yesterday the establishment of the 2018-2019 African Global...
Read moreIFPMA Statement on the G-FINDER Report “Landscape of Emerging Infectious Disease R&D: Preventing the Next Pandemic”
The latest G-Finder report “Landscape of Emerging Infectious Disease R&D: Preventing the next pandemic” shows that to be better prepared in the future, the R&D funding needs to be more diversified and supported by a wider range of funders. It also highlights the central role that product development partnerships (PDPs) and initiatives such as the...
Read moreIt’s Time to Agree on Universal Health Coverage Guiding Principles
With 1 billion people lacking access to basic health care and more than 2 billion people lacking regular access to essential medicines, governments are increasingly placing emphasis on the promise of universal health coverage (UHC). UHC has become an increasingly salient issue for developed and developing countries alike in the context of the global economic...
Read moreWorld Cancer Day 2014: Hand in Hand to Debunk Cancer Myths
Today, February 4th is World Cancer Day. This annual event is the ideal opportunity for millions of people to raise the profile of cancer around the world. The Union for International Cancer Control (UICC) and its 800 member organisations across 155 countries seek to press the world’s media to place cancer on their agendas and...
Read moreCreating a New Generation of Antibiotics webinar – opportunity to explain how pharma has stepped to the plate
I recently participated in Chatham House Webinar: Creating a New Generation of Antibiotics. It was a great opportunity for me to tell Jim O’ Neill, how little over a year ago, he played a role in speeding up industry action on AMR – something I had decided the IFPMA should engage on when I took...
Read moreFive Questions to …. Jane Barratt
We sat down with Dr. Jane Barratt, Secretary General, International Federation of Ageing to discuss the adoption of a life-course approach to health system challenges; the positive impact of adult vaccination across generations; and concrete policy recommendations to prevent the onset of dementia. The Decade of Healthy Ageing(2020-2030) has begun. Why should we adopt an...
Read moreProgress in tackling antimicrobial resistance
Since antibiotics were discovered nearly a century ago, the rate of resistance growth is outpacing the rate at which new ones can be developed and be used against infections. If we lose this race, patient deaths will significantly increase from the current 1.2 million per year. The pharmaceutical industry recognized the impending crisis and set...
Read more
By 2050, superbugs may cost the economy $100 trillion
This oped was first published in the Antimicrobial Resistance campaign in the Guardian on 12 November 2018 Antimicrobial resistance (AMR) is on course to overtake cancer and account for 10m deaths a year by 2050. Already, 700,000 people die from drug-resistant infections (“superbugs”) each year. AMR could cost the global economy up $100 trillion...
Read more